Dr. Tara B. Gregory, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Arizona College of Medicine (2004)
- Years since graduation
- 22
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 250
Licensed in Colorado since 2008, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2004Medical school: University of Arizona College of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CO license 47002 (first issued 2008; active) · AZ license 77380
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- HCA Healthone Presbyterian St. Lukes Denver, CO
Medical groups
- Select Physical Therapy of West Denver Limited PArtnership (548 clinicians)
- Healthone Clinic Services - Oncology Hematology LLC (47 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 250
- Services billed
- 32,871
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 7,740 | 24 |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 1,760 | 24 |
| Injection, magnesium sulfate, per 500 mg | 430 | 23 |
| Insertion of needle into vein for collection of blood sample | 411 | 81 |
| Established patient office or other outpatient visit, 40-54 minutes | 230 | 92 |
| Injection, ondansetron hydrochloride, per 1 mg | 200 | 15 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 144 | 48 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 107 | 48 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 105 | 63 |
| Administration of chemotherapy into vein, 1 hour or less | 77 | 41 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Denver, CO | 169 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Denver, CO | 75 |
| Jakafi (ruxolitinib phosphate) | 59 |
| Pomalyst (pomalidomide) | 48 |
| Prochlorperazine Maleate Other prescribers in Denver, CO | 47 |
| Gabapentin Other prescribers in Denver, CO | 42 |
| Amitriptyline Hcl Other prescribers in Denver, CO | 41 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Denver, CO | 41 |
| Dexamethasone Other prescribers in Denver, CO | 37 |
| Ondansetron Odt (ondansetron) Other prescribers in Denver, CO | 34 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 18 companies reported 44 payments worth $12,492 in total to this clinician.
| Janssen Scientific Affairs, LLC | $5,606 |
|---|---|
| Janssen Global Services, LLC | $4,200 |
| Janssen Biotech, Inc. | $1,685 |
| AbbVie Inc. | $296 |
| Beone Medicines USA, Inc. | $152 |
| Sanofi-aventis U.S. LLC | $107 |
| Geron Corporation | $65.67 |
| Astellas Pharma US Inc | $58.17 |
| Consulting Fee | $11,321 |
|---|---|
| Food and Beverage | $1,156 |
| Education | $15.33 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Scientific Affairs, LLC Jun 3, 2025 | Consulting Fee | $5,606 |
| Janssen Global Services, LLC Jul 15, 2025 | Consulting Fee CARVYKTI · Oncology | $2,450 |
| Janssen Global Services, LLC Aug 14, 2025 | Consulting Fee CARVYKTI · Oncology | $1,750 |
| Janssen Biotech, Inc. Feb 28, 2025 | Consulting Fee | $1,515 |
| GlaxoSmithKline, LLC. May 30, 2025 | Education OJJAARA · ONCOLOGY · in-kind | $15.33 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 13 industry-funded studies in 2025, from 5 companies. The companies reported $683,710 in research payments for these studies, mostly to the institutions running them.
- A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
Celgene Corporation - A Phase 1b/2 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Relapsed/Refractory Multiple Myeloma
AstraZeneca Pharmaceuticals LP - Randomized, open-label, Phase 3 trial to evaluate efficacy and safety of ide-cel with lenalidomide maintenance (Arm A) versus lenalidomide maintenance therapy (Arm B) in adult NDMM patients with suboptimal response af…
Celgene Corporation - A phase 1, multicenter, open-label study of cc 95266, g protein-coupled receptor class c group 5 member d (GPRC5D)-targeted chimeric antigen receptor (car) t cells, in subjects with relapsed and/or refractory multiple…
Celgene Corporation - A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
E.r. Squibb & Sons, L.l.c. - Phase I, Open Label, Study of B-cell Maturation Antigen (BCMA)-Directed CAR-T Cells in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Novartis Pharmaceuticals Corporation - A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Release in Patients with Multiple Myeloma
Janssen Research & Development, LLC - Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel (ide-cel) that is Non-conforming for Commercial Release
Celgene Corporation - A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous St…
Janssen Research & Development, LLC - Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Celgene Corporation · Recruiting · NCT03435796
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.